CALAA‐01: CALAA‐01 was a pioneering targeted siRNA nanotherapeutic that was developed by Davis in 1996.237 This delivery system consists of an anti‐RRM2 (ribonucleotide reductase subunit 2) siRNA payload and cyclodextrin‐containing polymer particle core attached with AD–PEG group and some AD–PEG covalently linked to human transferrin (Tf–PEG–AD) for tumor targeting and cellular internalization. Here, TF is linked to neoplasm.